Component

Urinary albumin excretion

Independent biological entity. Read linked claims for experimental scope and context.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Twelve weeks of benfotiamine did not significantly reduce urinary albumin or KIM-1 excretion despite improved thiamine status.

    Benfotiamine → Urinary albumin excretion source_derived_draftungraded
    Experimental context and source evidence
    experimental_model
    82 participants already receiving ACE inhibitor or ARB therapy.
    exposure
    Benfotiamine 900 mg/day versus placebo for 12 weeks on ACE inhibitor/ARB therapy; study exposure only.
    limitations
    Different compound, population and treatment context from the native-thiamine pilot; not a direct replication or proven explanation for the difference.
    nutrient_topic
    Thiamine research collection; topical membership is not evidence of a direct dietary effect. · Thiamine (vitamin B1)
    organism
    Homo sapiens
    plain_language
    Higher vitamin status did not translate into the expected kidney-marker improvement.
    primary_references
    [b1-alkhalaf2010] A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy (2010). https://pubmed.ncbi.nlm.nih.gov/20413516/ DOI: 10.2337/dc09-2241
    tissue_or_cell_type
    Urine

    Thiamine: mechanisms, deficiency and nutrient interactions (2026-09-17) · lines 1855–1865

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · 82 participants already receiving ACE inhibitor or ARB therapy. · source_derived_draft · unverified_draft

    ### b1-benfotiamine-kidney-null Twelve weeks of benfotiamine did not significantly reduce urinary albumin or KIM-1 excretion despite improved thiamine status. Condition category: normal nutrient_topic: Thiamine research collection; topical membership is not evidence of a direct dietary effect. plain_language: Higher vitamin status did not translate into the expected kidney-marker improvement. organism: Homo sapiens tissue_or_cell_type: Urine experimental_model: 82 participants already receiving ACE inhibitor or ARB therapy. limitations: Different compound, population and treatment context from the native-thiamine pilot; not a direct replication or proven explanation for the difference. exposure: Benfotiamine 900 mg/day versus placebo for 12 weeks on ACE inhibitor/ARB therapy; study exposure only. [b1-alkhalaf2010] A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy (2010). https://pubmed.ncbi.nlm.nih.gov/20413516/ DOI: 10.2337/dc09-2241
    Complete structured claim and evidence

  2. In the 40-person pilot, urinary albumin excretion was lower after three months of thiamine than placebo; glycemic control, lipids and blood pressure did not change significantly.

    Thiamine (vitamin B1) → Urinary albumin excretion source_derived_draftungraded
    Experimental context and source evidence
    experimental_model
    Type 2 diabetes with microalbuminuria.
    exposure
    Three 100 mg thiamine capsules daily versus placebo for three months, then two-month washout; study exposure only.
    limitations
    Small short trial; no long-term kidney-failure outcome and no isolated proof of transketolase mediation.
    nutrient_topic
    Thiamine research collection; topical membership is not evidence of a direct dietary effect. · Thiamine (vitamin B1)
    organism
    Homo sapiens
    plain_language
    A small trial suggested a renal biomarker benefit without showing its molecular cause.
    primary_references
    [b1-rabbani2009] High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study (2009). https://pubmed.ncbi.nlm.nih.gov/19057893/ DOI: 10.1007/s00125-008-1224-4
    tissue_or_cell_type
    Urine

    Thiamine: mechanisms, deficiency and nutrient interactions (2026-09-17) · lines 1843–1853

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Type 2 diabetes with microalbuminuria. · source_derived_draft · unverified_draft

    ### b1-diabetes-thiamine-albuminuria In the 40-person pilot, urinary albumin excretion was lower after three months of thiamine than placebo; glycemic control, lipids and blood pressure did not change significantly. Condition category: normal nutrient_topic: Thiamine research collection; topical membership is not evidence of a direct dietary effect. plain_language: A small trial suggested a renal biomarker benefit without showing its molecular cause. organism: Homo sapiens tissue_or_cell_type: Urine experimental_model: Type 2 diabetes with microalbuminuria. limitations: Small short trial; no long-term kidney-failure outcome and no isolated proof of transketolase mediation. exposure: Three 100 mg thiamine capsules daily versus placebo for three months, then two-month washout; study exposure only. [b1-rabbani2009] High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study (2009). https://pubmed.ncbi.nlm.nih.gov/19057893/ DOI: 10.1007/s00125-008-1224-4
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards